)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Cardiff Oncology
Cardiff Oncology (CRDF) investor relations material
Cardiff Oncology H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary14 Sep, 2026
Settlement and licensing agreement
Reached an out-of-court settlement with Nerviano Medical Sciences, resolving all claims and disputes.
Retained exclusive worldwide rights, inventorship, and unchanged royalty rates for onvansertib.
Royalty period extended beyond the previous 2035 term, with Nerviano receiving a board observer seat.
Phase III trial design and regulatory alignment
Phase III trial for onvansertib in first-line RAS mutated metastatic colorectal cancer will enroll about 640 patients, randomized 1:1.
Primary endpoint is overall response rate (ORR), with progression-free survival (PFS) as a secondary endpoint.
FDA allowed for potential accelerated approval based on ORR and durability, with full approval possible based on PFS.
Study is powered with over 90% probability to show a clinically meaningful PFS difference.
Competitive landscape and scientific rationale
Onvansertib targets all RAS mutations, unlike allele-specific inhibitors that address only small patient subsets.
PLK1 inhibition offers a parallel pathway to RAS, potentially avoiding resistance seen with other approaches.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cardiff Oncology
- Vote to increase authorized shares aims to support future growth and financing flexibility.CRDF
Proxy filing - Shareholders will vote on a major increase in authorized shares at the October 2026 meeting.CRDFProxy filing
- Vote sought to increase authorized shares and permit meeting adjournment if needed.CRDFProxy filing
- Phase 2 success for onvansertib in mCRC; cash runway into Q3 2027, but litigation risk remains.CRDFQ2 2026
- Onvansertib shows strong efficacy and safety in first-line RAS-mutated MCRC, with major updates due in Q1 2026.CRDFNoble Capital Markets Emerging Growth Virtual Investor Conference
- Advancing a well-tolerated PLK1 inhibitor to global phase III for RAS-mutated colorectal cancer.CRDFJefferies Global Healthcare Conference 2026
- 30 mg onvansertib plus FOLFIRI-BEV delivers 72.2% ORR and durable benefit in RAS-mutated mCRC.CRDFStatus update
- Positive Phase 2 data, FDA alignment, and narrowed net loss offset by ongoing going concern risk.CRDFQ1 2026
- Annual meeting covers director elections, auditor ratification, equity plan amendment, and say-on-pay.CRDFProxy filing
Next Cardiff Oncology earnings date
Q3 20266 Nov, 2026
Cardiff Oncology
Next Cardiff Oncology earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage